Lille (France), April 8th, 2021 – Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces today today hat it has established its US based subsidiary, Alzprotect US Inc. in Boston, Massachusetts, in line with its international development strategy.

This new subsidiary of Alzprotect is situated in Boston. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technological innovation and ideally suited for Alzprotect’ first US foothold.

The creation of this affiliate is the first milestone in a process that will lead to the initiation of Alzprotect’ clinical trials for the treatment of PSP and Alzheimer’s disease in the US.

Dr Philippe Verwaerde, CEO of Alzprotect, commented: “The creation of a subsidiary in the US is an important step forward in our strategy as set out in our future development. This further strengthens the international reach of our innovative pipeline for the treatment of neurodegeneration. We are very excited to become part of the biotechnology cluster in Cambridge and believe this prime location will prove to be extremely beneficial to the Company as we move our clinical development forward in this important market.”

Back to news